NCT05659563 2026-03-19
EMPRESS
MedSIR
Phase 2 Completed
Clinical Trials
142 trialsNCT00893061 2026-03-17
MNEMOSYNE
Centre Oscar Lambret
Phase 3 Completed
NCT06982313 2026-03-11
Babytam long
Ente Ospedaliero Ospedali Galliera
Completed
NCT00003042 2026-02-20
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT05101564 2026-02-12
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Stanford University
Phase 2 Completed
NCT00066690 2026-02-06
SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT02668666 2026-01-20
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT02630693 2025-11-25
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT07145827 2025-09-12
Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen
Uruk University
Phase NA Completed
NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
NCT00601900 2025-05-23
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT03346200 2025-03-07
KARISMA2
Karolinska Institutet
Phase 2 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT00667121 2025-02-14
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
Mayo Clinic
Completed
NCT00949598 2025-02-13
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 3 Completed
NCT04079517 2025-02-06
Karisma-1
Karolinska Institutet
Phase 1/2 Completed
NCT02993159 2024-12-18
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Northwestern University
Phase 2 Completed
NCT00002644 2024-12-11
IBIS-1
Queen Mary University of London
Phase 3 Completed
NCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT02913430 2024-09-23
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT04129216 2024-05-07
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT00295646 2024-03-15
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT02278120 2024-03-12
MONALEESA-7
Novartis
Phase 3 Completed
NCT00424164 2024-03-08
LAPATAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT01298713 2023-09-06
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT00309478 2023-06-29
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT01124695 2023-06-29
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00004125 2023-06-15
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT02333370 2023-06-08
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT00433589 2022-11-17
MINDACT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT02285179 2022-10-12
Poseidon
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT03948568 2022-09-30
REaCT-RETT
Ottawa Hospital Research Institute
Phase 4 Completed
NCT00003857 2022-05-25
Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
Radiation Therapy Oncology Group
Phase 3 Completed
NCT02384239 2022-03-16
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
University of California, San Francisco
Phase 2 Completed
NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02988986 2021-09-22
ANETT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT01220076 2021-03-12
TAM
Institut Cancerologie de l'Ouest
Phase 2 Completed
NCT01192308 2020-12-01
KINETAM
Radboud University Medical Center
Phase 1 Completed
NCT00309491 2020-10-19
Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT00005970 2020-08-14
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01950182 2020-07-15
SYSUCC-002
Sun Yat-sen University
Phase 3 Completed
NCT00002542 2020-04-01
Tamoxifen in Treating Women With High-Risk Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00002864 2020-04-01
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00003032 2020-04-01
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT02866955 2020-03-09
EFESE
Institut de Cancérologie de Lorraine
Phase 2 Completed